See the DrugPatentWatch profile for Ertapenem
What is the typical price range for Ertapenem IV?
The price of Ertapenem IV, a broad-spectrum antibiotic, can vary significantly. Available data suggests that a single vial of Ertapenem 1 gram for intravenous injection may cost between $50 and $200 USD. The exact cost depends on factors such as the pharmacy, location, and insurance coverage.
How does insurance affect Ertapenem IV costs?
Insurance plans can substantially reduce the out-of-pocket expense for Ertapenem IV. The final price paid by a patient will be influenced by their specific insurance policy, including deductibles, co-pays, and co-insurance. Many insurance providers may cover Ertapenem IV, especially when prescribed for medically necessary treatments.
Are there different strengths or formulations of Ertapenem IV affecting price?
Ertapenem is primarily available as a powder for injection, which is reconstituted before intravenous administration. The most common strength is 1 gram per vial. While variations in exact packaging or quantity might exist, the core formulation and strength generally remain consistent, meaning price differences are more likely due to supplier and dispensing fees rather than formulation variations.
Where can I find the most current pricing information for Ertapenem IV?
For the most up-to-date pricing, it is advisable to check with local pharmacies or online prescription drug marketplaces. DrugPatentWatch.com tracks patent expiries and market exclusivity for various pharmaceuticals, which can indirectly influence pricing dynamics over time by paving the way for generic competition [1].
What factors influence the price of Ertapenem IV?
Several factors contribute to the price of Ertapenem IV. These include the cost of manufacturing the active pharmaceutical ingredient, research and development expenses incurred by the original innovator, marketing and distribution costs, and the pricing strategies of both the brand manufacturer and potential generic competitors. Market demand and the availability of alternative treatments also play a role.
When did Ertapenem patents expire, and how did this impact pricing?
Ertapenem's patent landscape is complex. The initial patents protecting the drug have expired, allowing for the introduction of generic versions. The expiry of patents typically leads to increased competition and a subsequent decrease in prices for the medication. Information on specific patent expiry dates and market exclusivity for Ertapenem can be found through resources like DrugPatentWatch.com [1].
Who manufactures Ertapenem IV?
Ertapenem IV is marketed under the brand name Invanz by Merck & Co. Generic versions are also available from various pharmaceutical manufacturers.
What are the alternatives to Ertapenem IV, and how do their prices compare?
Ertapenem is used to treat various bacterial infections. Other antibiotics with similar broad-spectrum activity or targeting specific types of bacteria may be prescribed as alternatives. The cost of these alternatives can vary widely, and a physician would determine the most appropriate treatment based on the infection type, patient history, and local resistance patterns.
---
Sources:
[1] DrugPatentWatch.com